{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:52:58Z","timestamp":1792669978616,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"35","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,12,10]]},"abstract":"<jats:p>The phase II PHAROS study previously showed that encorafenib plus binimetinib has antitumor activity in patients with BRAF V600E-mutant metastatic non\u2013small cell lung cancer (mNSCLC). In PHAROS, 98 patients (59 treatment-na\u00efve; 39 previously treated) received encorafenib 450 mg once daily and binimetinib 45 mg twice daily. We report updated results from data cutoff of March 14, 2025. The median duration of treatment with both encorafenib and binimetinib was 16.3 months in treatment-na\u00efve and 5.5 months in previously treated patients. After median follow-up for overall survival (OS) of 52.3 months in treatment-na\u00efve patients, mOS was 47.6 months (95% CI, 31.3 to not estimable); 4-year OS probability was 49% (95% CI, 35 to 62). After median follow-up for OS of 48.2 months in previously treated patients, mOS was 22.7 months (95% CI, 14.1 to 32.6); 4-year OS probability was 31% (95% CI, 16 to 47). In treatment-na\u00efve and previously treated groups, 58% and 26% received \u22651 subsequent systemic anticancer treatment, respectively. Safety profile remained consistent with that in previous analyses. Although comparisons across trials should be done cautiously, to our knowledge, encorafenib plus binimetinib was associated with the longest mOS reported to date with targeted treatment in patients with treatment-na\u00efve BRAF V600E-mutant mNSCLC.<\/jats:p>","DOI":"10.1200\/jco-25-02023","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T07:33:26Z","timestamp":1760859206000},"page":"3706-3713","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":18,"title":["Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non\u2013Small Cell Lung Cancer"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03915951","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":true,"given":"Melissa L.","family":"Johnson","sequence":"first","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-6995","authenticated-orcid":true,"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":true,"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":true,"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9654","authenticated-orcid":true,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-6639","authenticated-orcid":true,"given":"Anne","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head &amp; Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-3677","authenticated-orcid":true,"given":"Bruce E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":true,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-6776","authenticated-orcid":true,"given":"Maen","family":"Hussein","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists, Sarah Cannon Research Institute, Leesburg, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-9257","authenticated-orcid":true,"given":"Ibiayi","family":"Dagogo-Jack","sequence":"additional","affiliation":[{"name":"Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-8243","authenticated-orcid":true,"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6699","authenticated-orcid":true,"given":"Marcelo V.","family":"Negrao","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head &amp; Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":true,"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[{"name":"Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-2028","authenticated-orcid":true,"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Usari","sequence":"additional","affiliation":[{"name":"Pfizer, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-7865","authenticated-orcid":true,"given":"Keith","family":"Wilner","sequence":"additional","affiliation":[{"name":"Pfizer, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Alejandro","sequence":"additional","affiliation":[{"name":"Pfizer, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7627-9519","authenticated-orcid":true,"given":"Nada","family":"Rifi","sequence":"additional","affiliation":[{"name":"Pfizer, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-4313","authenticated-orcid":true,"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_12_2_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0458"},{"key":"e_1_3_12_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0657"},{"key":"e_1_3_12_4_2","article-title":"BRAF in lung cancers: Analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations","author":"Sheikine Y","unstructured":"Sheikine Y, Pavlick D, Klempner SJ, et al: BRAF in lung cancers: Analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations. JCO Precis Oncol 10.1200\/PO.17.00172","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_12_6_2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. Version 7.2025. https:\/\/www.nccn.org"},{"key":"e_1_3_12_7_2","unstructured":"US Food and Drug Administration: FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-dabrafenib-and-trametinib-combination-metastatic-nsclc-braf-v600e"},{"key":"e_1_3_12_8_2","unstructured":"US Food and Drug Administration: FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation"},{"key":"e_1_3_12_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2923"},{"key":"e_1_3_12_10_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1250"},{"key":"e_1_3_12_11_2","volume-title":"BRAFTOVI (encorafenib) [package insert]","author":"Array BioPharma Inc","unstructured":"Array BioPharma Inc: BRAFTOVI (encorafenib) [package insert]. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12990"},{"key":"e_1_3_12_12_2","volume-title":"MEKTOVI (binimetinib) [package insert]","author":"Array BioPharma Inc","unstructured":"Array BioPharma Inc: MEKTOVI (binimetinib) [package insert]. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12988"},{"key":"e_1_3_12_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00774"},{"key":"e_1_3_12_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.05.023"},{"key":"e_1_3_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"e_1_3_12_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4"},{"key":"e_1_3_12_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.011"},{"key":"e_1_3_12_18_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078"},{"key":"e_1_3_12_19_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-4218"},{"key":"e_1_3_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.04.016"},{"key":"e_1_3_12_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1358"},{"key":"e_1_3_12_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8574"},{"key":"e_1_3_12_23_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-613"},{"key":"e_1_3_12_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05510-4"},{"key":"e_1_3_12_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-139"},{"key":"e_1_3_12_26_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0348"},{"key":"e_1_3_12_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz077"},{"key":"e_1_3_12_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.001"},{"key":"e_1_3_12_29_2","doi-asserted-by":"publisher","DOI":"10.14252\/foodsafetyfscj.D-22-00008"},{"key":"e_1_3_12_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000191"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T23:00:25Z","timestamp":1764975625000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":29,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025,12,10]]}},"alternative-id":["10.1200\/JCO-25-02023"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02023","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"2025-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}